Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.

Francesca BareiMartina ZussinoSimona TavecchioLuisa AngileriArianna RizzoPaolo CalzariAngelo V MarzanoSilvia Mariel Ferrucci

Published in: Pharmaceuticals (Basel, Switzerland) (2024)

Dupilumab's benefits endure beyond the first year, emphasizing its long-term efficacy, and consistently improves AD outcomes regardless of individual characteristics or clinical variables. ADCT appears to be a practical and versatile tool for the streamlined assessment of AD treatment outcomes.

Keyphrases

atopic dermatitis
patient reported outcomes
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
type diabetes
early onset
metabolic syndrome
insulin resistance
glycemic control
replacement therapy
clinical evaluation